share_log

Johnson & Johnson | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

Johnson & Johnson | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

強生 | FWP:自由書寫募資說明書
美股sec公告 ·  05/14 17:04
Moomoo AI 已提取核心訊息
Johnson & Johnson, the global healthcare company, has announced the pricing of its multi-tranche notes offering on May 14, 2024. The offering includes 3.200% notes due 2032, 3.350% notes due 2036, and 3.550% notes due 2044, with a total size of €2.5 billion. The notes are expected to settle on May 20, 2024, and will be listed on the New York Stock Exchange. The proceeds from the offering are anticipated to be used for general corporate purposes. The notes have been rated Aaa (stable) by Moody's and AAA (negative) by S&P. The joint book-running managers for the offering include J.P. Morgan Securities, Citigroup Global Markets, and several other notable financial institutions. The offering is targeted at eligible counterparties and professional clients only, with sales to EEA/UK retail investors being prohibited.
Johnson & Johnson, the global healthcare company, has announced the pricing of its multi-tranche notes offering on May 14, 2024. The offering includes 3.200% notes due 2032, 3.350% notes due 2036, and 3.550% notes due 2044, with a total size of €2.5 billion. The notes are expected to settle on May 20, 2024, and will be listed on the New York Stock Exchange. The proceeds from the offering are anticipated to be used for general corporate purposes. The notes have been rated Aaa (stable) by Moody's and AAA (negative) by S&P. The joint book-running managers for the offering include J.P. Morgan Securities, Citigroup Global Markets, and several other notable financial institutions. The offering is targeted at eligible counterparties and professional clients only, with sales to EEA/UK retail investors being prohibited.
全球醫療保健公司強生於2024年5月14日宣佈了其多批票據發行的定價。此次發行包括2032年到期的3.200%的票據、2036年到期的3.350%的票據和2044年到期的3.550%的票據,總規模爲25億歐元。這些票據預計將於2024年5月20日結算,並將在紐約證券交易所上市。此次發行的收益預計將用於一般公司用途。這些票據被穆迪評爲Aaa(穩定),標準普爾將這些票據評爲AAA(負值)。此次發行的聯合賬面管理人包括摩根大通證券、花旗集團環球市場和其他幾家知名金融機構。此次發行僅針對符合條件的交易對手和專業客戶,禁止向歐洲經濟區/英國散戶投資者進行銷售。
全球醫療保健公司強生於2024年5月14日宣佈了其多批票據發行的定價。此次發行包括2032年到期的3.200%的票據、2036年到期的3.350%的票據和2044年到期的3.550%的票據,總規模爲25億歐元。這些票據預計將於2024年5月20日結算,並將在紐約證券交易所上市。此次發行的收益預計將用於一般公司用途。這些票據被穆迪評爲Aaa(穩定),標準普爾將這些票據評爲AAA(負值)。此次發行的聯合賬面管理人包括摩根大通證券、花旗集團環球市場和其他幾家知名金融機構。此次發行僅針對符合條件的交易對手和專業客戶,禁止向歐洲經濟區/英國散戶投資者進行銷售。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息